| Document Date: 2015-04-22 04:48:43
Open Document File Size: 201,58 KBShare Result on Facebook
City Shanghai / Ingelheim / Dortmund / / Company Ben Venue Laboratories / Boehringer Ingelheim Annual Press / Boehringer Ingelheim’s Annual Press / Managing Directors Check / Corporate Board Divisions Human Resources / / Continent Americas / / Country Germany / Japan / United States / China / / Currency EUR / / Event M&A / / Facility Boehringer Ingelheim Center / D laboratory / / IndustryTerm pharmaceutical industry / treatment of chronic obstructive pulmonary disease / treatment of hypertension / pharmaceutical / respiratory product / / MedicalCondition hypertension / disease / idiopathic pulmonary fibrosis / chronic obstructive pulmonary disease / advanced lung cancer / diabetes / adenocarcinoma following chemotherapy Allow / / MedicalTreatment innovative therapies / chemotherapy / / Organization Board of Managing Directors / Corporate Board Divisions Human Resources and Research / US Food and Drug Administration / / Person Andreas Barner / Andreas Barner Hubertus von Baumbach / / Position Chairman / important and long-term growth driver / / Product COMBIVENT / SPIRIVA / MICARDIS / / Technology chemotherapy / /
SocialTag |
Boehringer Ingelheim Annual Press Conference 2015 Wednesday, 22 April 2015 Boehringer Ingelheim Center, Ingelheim, Germany